Latest Chronic obstructive pulmonary disease Stories
Sales of the LABA/LAMA Combination Drug Class are Expected to Grow Significantly Over the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Despite Cost and Coverage Constraints, Physicians Manage to Prescribe LABA and LAMA Regimens in Combination for COPD, According to Findings from Decision Resources Group BURLINGTON, Mass.,
For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
The microdevice can provide new insights in disease studies and drug discovery by mimicking the complex multicellular structure and function of human airway tissue. Research
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
New site is filled with information, patient testimonials, easy-to-use tools and real-world tips for people affected by COPD RESEARCH TRIANGLE PARK, N.C., Aug.
New Study Published in The Lancet Respiratory Medicine is First to Provide Strong Evidence Supporting Long-term NPPV in the Treatment of COPD SAN DIEGO, Aug.
For U.S. Media Only RIDGEFIELD, Conn., Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
COPD is one of the many chronic lower respiratory diseases which are currently the number three leading cause of death of Americans. COPD claimed almost 135,000 lives in 2011.
- a slit in a tire to drain away surface water and improve traction.